

CALL FOR PROPOSALS

SPARK TEL AVIV - ICHILOV Mentoring Program

Proposals 2025-2026

Novel Therapeutics and Drug Repurposing Track

Advancing the Translation of Academic Discoveries to
Clinical Practice



We are pleased to announce the launch of the 1st joint Call For Proposals of SPARK TEL AVIV, TAU and Tel Aviv Sourasky Medical Center (ICHILOV) focused on ADVANCING NOVEL THERAPEUTICS and DRUG REPURPOSING to the CLINIC.

[SPARK TEL AVIV](#) is a mentoring program dedicated to accelerating scientific discoveries and expanding the societal impact of academic innovations. It is a member of the '[SPARK Global](#)' community, founded by Stanford University, and specializes in the field of translational medicine.

Our mission is to help researchers from TAU and TASMC navigate the challenges of translating their research discoveries into new therapies. The 'Novel Therapeutics and Repurposing track' is designed to support the transition from academic proof-of-concept studies to fully developed products, as well as preclinical and clinical trials that meet industry standards.

The call is open for two tracks:

1. Development of NOVEL THERAPEUTICS (small molecule or biologics), MEDICAL DEVICES, and DIAGNOSTICS for UNMET MEDICAL NEEDS
2. REPURPOSING OF EXISTING DRUGS (approved or investigational drugs) for new indications that are outside the scope of the original medical indication.

Awarded projects will receive milestone-based funding for two years, up to \$100,000 per project/year. Funded projects will also receive ongoing mentorship, access to expert advisors, and educational program throughout all stages of product development. The program will support expenses needed for taking the project towards clinical study, including pre-clinical studies, patient profiling, regulatory consultancy, clinical trial protocol development, product design, and efforts required for clinical readiness.

ELIGIBILITY AND PRIORITY

- Applications will be accepted from Active and Prolific Collaboration between Regular full-time TAU Researchers (NOT emeritus) and TASMC Researchers (M.D./Ph.D.)
- Invited applications are for projects in the pre-translational phase, where proof of concept has already been established (e.g. in vivo results) and implementation is possible within 2 years.

CRITERIA

- Scope of UNMET CLINICAL NEED
- NOVELTY of approach
- TEAM suitability
- Quality of DATA
- Probability of COMMERCIALIZATION for Novel Therapeutics
- FEASIBILITY (Budget and time)

YOUR BENEFIT:

- Funding to de-risk your project
- Advice from industry leaders and access to experts
- Project management support and mentorship
- Education on drug development and clinical readiness
- Membership in the global SPARK community and network
- Support for bringing your invention to the clinic

HOW TO APPLY?

- Use the application form at the SPARK TEL AVIV website <https://spark-telaviv.tau.ac.il>,
• **Deadline: September 20, 2025.**
- Applications will be reviewed by an academic committee from TAU and ICHILOV and external key opinion leaders in the relevant fields.
 - Final decision will be announced during **December 2025**
- The selected projects will participate in monthly educational lectures. Participation is obligatory.